Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies.
OBJECTIVE
Urodynamic investigations provide an objective, quantitative evaluation of urinary function in patients with benign prostatic obstruction (BPO). The effects of doxazosin, a selective alpha 1-adrenoceptor antagonist, on urodynamic measurements were investigated in three double-blind, placebo-controlled clinical studies of the treatment of BPO.


METHODS
302 normotensive and mildly hypertensive men with BPO were evaluated. Patients were randomized to receive doxazosin (1-4 mg o.d.) or placebo for 4-29 weeks.


RESULTS
Doxazosin significantly improved free urinary flow rates compared with placebo. Urodynamic studies confirmed that doxazosin was effective in improving urinary flow, and also showed a reduction in detrusor pressure, resulting in decreased voiding time and increased voided volume. Analysis of pressure-flow data demonstrated a significant reduction in a measure of urethral resistance in doxazosin-treated patients.


CONCLUSIONS
These results indicate that doxazosin is an important treatment option for patients with troublesome lower urinary tract symptoms and BPO.
Abrams
P
P
Bristol Urological Institute, Southmead General Hospital, Westbury-on-Trym, UK.
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D003718:Denmark; D004311:Double-Blind Method; D017292:Doxazosin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D009426:Netherlands; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D006113:United Kingdom; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy*; D014554:Urination / Q000187:drug effects; D014563:Urodynamics / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin